

## Oesophageal & Gastric Cancer

---

Reference Number: F4778  
Date of Response: 31/08/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

### **Royal Devon's Eastern FOI Office Response**

FOI Questions:

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin) – **6 Patients**
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) – **0 Patients**
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) – **0 Patients**
- Any other systemic anti-cancer therapy – **10 Patients**
- Palliative care only – **0 Patients**

Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) – **\* Patients**
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) – **9 Patients**
- Nivolumab monotherapy – **0 Patients**
- Nivolumab and Ipilimumab – **0 Patients**
- Any other systemic anti-cancer therapy – **16 Patients**
- Palliative care only – **0 Patients**

**\* - low value suppressed to protect patient identity - <5.**

Q3. Of the Oesophageal Cancer patients (from Q2) treated with Pembrolizumab in the past 3 months, how many patients were treated for:

- Oesophageal adenocarcinoma – **\* Patients**
- Oesophageal squamous cell carcinoma – **0 Patients**

**\* - low value suppressed to protect patient identity - <5.**

Q4. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with:

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) – **\* Patients - <5.**
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) – **8 Patients**

- Nivolumab monotherapy – **0 Patients**
- Nivolumab and Ipilimumab – **0 Patients**
- Any other systemic anti-cancer therapy – **5 Patients**
- Palliative care only – **0 Patients**

\* - low value suppressed to protect patient identity <5.

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.